PUBLISHER: QYResearch | PRODUCT CODE: 1860000
PUBLISHER: QYResearch | PRODUCT CODE: 1860000
The global market for Albumin (as Excipient) was estimated to be worth US$ 1594 million in 2024 and is forecast to a readjusted size of US$ 2454 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Albumin (as Excipient) cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Albumin excipients refer to human serum albumin (HSA) or recombinant human serum albumin (rHSA) used as excipients in biopharmaceuticals. Their primary functions include stabilizing the structure and activity of protein drugs, enhancing drug solubility and bioavailability as carriers, and serving as nutritional components in vaccines and cell culture media. With the advancement of biologics and vaccine development, the application of albumin excipients in drug formulations is becoming increasingly widespread.In 2024, global Albumin (as Excipient) production reached approximately 440 mt, with an average global market price of around US$ 3622 per kg.
The albumin excipient market is experiencing unprecedented growth opportunities due to the global rise in chronic diseases, rapid expansion of the biopharmaceutical industry, and increasing demand for efficient drug delivery systems. Particularly in vaccine development and gene therapy, albumin excipients have become indispensable components due to their excellent biocompatibility and stability. Furthermore, advancements in recombinant albumin technologies have made the production process safer and more controllable, further driving market growth.
Despite the promising prospects, the albumin excipient market faces several challenges. Firstly, the source and quality control of raw materials are critical, especially the supply of human-derived albumin, which may affect production stability. Secondly, stringent regulatory requirements and quality standards make the research and development process complex and time-consuming. Additionally, increasing market competition from emerging enterprises and technologies may threaten the market share of existing companies.
Downstream demand is primarily concentrated in areas such as vaccines, cell culture media, protein drugs, and gene therapies. With the rise of personalized medicine and precision therapy, the demand for high-quality excipients continues to increase. Moreover, the growing aging population globally is driving the demand for chronic disease treatment drugs, thereby boosting the need for albumin excipients.
The main raw materials for albumin excipients include human serum albumin and recombinant bovine serum albumin. Human serum albumin is primarily sourced from plasma collection; however, its supply is limited by the number of blood donors and ethical issues related to plasma collection. On the other hand, recombinant bovine serum albumin production relies on bioreactor technology, which has higher production costs and technical requirements. Therefore, the stable supply and cost control of raw materials are key factors influencing the development of the albumin excipient market.
This report aims to provide a comprehensive presentation of the global market for Albumin (as Excipient), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Albumin (as Excipient) by region & country, by Type, and by Application.
The Albumin (as Excipient) market size, estimations, and forecasts are provided in terms of sales volume (MT) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Albumin (as Excipient).
Market Segmentation
By Company
Segment by Type
Segment by Application
By Region
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Albumin (as Excipient) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Albumin (as Excipient) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Albumin (as Excipient) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.